Qualifying Notice for Gavreto

Qualifying Notice for Gavreto This Notice of Compliance with Conditions Qualifying Notice (NOC/c-QN), issued in accordance with the Health Canada Guidance Document: Notice of Compliance with Conditions (NOC/c), is to advise you that information submitted in support of the New Drug Submission for Gavreto (pralsetinib), Control Number 243731, for the indication of the treatment of adult patients with rearranged during transfection (RET) fusion-positive locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC). 2023-11-01 Health Canada open-ouvert@tbs-sct.gc.ca Health and Safetyqualifying noticeGavretonotice-of-compliance with conditions-qualifying noticeNOC/c-QN Qualifying Notice for GavretoHTML https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions/qualifying-notice-gavreto-243731.html Qualifying Notice for GavretoHTML https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/avis-conformite/conditions/avis-admissibilite-gavreto-243731.html

This Notice of Compliance with Conditions Qualifying Notice (NOC/c-QN), issued in accordance with the Health Canada Guidance Document: Notice of Compliance with Conditions (NOC/c), is to advise you that information submitted in support of the New Drug Submission for Gavreto (pralsetinib), Control Number 243731, for the indication of the treatment of adult patients with rearranged during transfection (RET) fusion-positive locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC).

Data and Resources

Similar records